Sign in by typing your Id and password
Settings
Help
Active immunotherapy in advanced melanoma patients
Clinical protocolThe vaccine is composed by autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3).
Protocol Steps:
-
Electroporation
Electroporation of autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce the vaccine
-
Vaccination of patients
Advanced melanoma patients are vaccinated with the DC vaccine.
- biomaterial type
- dendritic cell,
- melanoma antigen MAGE-3,
- CD70,
- gp100 antigen,
- CD40 ligand,
- Toll like receptor 4,
- tyrosinase,
- messenger RNA
created over 16 years ago
(2 March 2009)
last modified over 13 years ago
(28 September 2011)
[ RDF 
]
[ RelFinder 
]